Abstract 1481P
Background
ICIs have transformed the treatment of advanced NSCLC patients, no real-world data are available about the immune-related adverse events (irAEs). This retrospective study aimed to assess the safety and effectiveness of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer (NSCLC) and to analyze the association between singular irAEs and effectiveness.
Methods
This was a retrospective study of the clinical data of patients with NSCLC treated with PD-1/PD-L1 inhibitors as 1a or 2a lines from Marzo 2015 to Marzo 2022 at Hospital Universitario Regional de Málaga. We evaluated association of irAE with efficacy, response and overall survival. Kaplan-Meier and Cox proportional hazard analyses were performed.
Results
A total of 510 patients were included in this analysis. Any grade IrAEs were seen in 307 (60%) patients. Of these (Table), 135 (43,9%) patients had grade 1 toxicities, most commonly cutaneous (96), colitis (54), rheumatologic (46) and hepatitis (42). 112 (36,4%) patients had grade 2 toxicities pneumonitis (47), cutaneous (29), colitis (28). 53 (17,2%) patients had grade 3 toxicities: hepatitis (15), pneumonitis (13), cutaneous (10). 8 (2,6 %) patients had grade 4 toxicities hepatitis (5), pneumonitis (2), DRESS syndrome (1). For patients assessed for efficacy, objective response rate (ORR) to ICI was higher in patients with irAEs [46% vs 14%] p=0,001. In fact, the presence of any irAEs had a significantly improved median OS compared to those without irAEs (19,3 months vs 6,5 p = 0.0001) (Median OS in G1-2 20 months and G 3-4 16,2 months had significally higher OS vs non irAEs 6,1 months; p=0,0001). Singular toxicities that predict greater OS >30 months were (Hepatitis G4, endocrine G1 and cutaneous G2); point out toxicities with deleterious effects (colitis G3 and pneumonitis G4). Multivariable analysis demonstrated that the development of any irAEs was related to a significantly improved OS (HR 0.47, 95% 0.26-0.68, p = 0.0001).
Table: 1481P
Summary of singular toxicities and OS (overall survival) in months
IrAEsN 307 | Cutaneous 135 OS | Pneumo92 OS | Colitis89 OS | Hepatitis79 OS | Rheuma76 OS | Endocrine61 OS | Renal40 OS |
G1 135 | 96 28.2 | 29 18.3 | 54 21.4 | 42 18.7 | 46 28.8 | 40 37.8 | 19 21.4 |
G2 112 | 29 31.1 | 47 13.8 | 28 21.4 | 17 19 | 28 20.1 | 18 28.8 | 14 28.2 |
G3 53 | 10 13.4 | 13 15.3 | 7 7.2 | 15 20.6 | 2 3.8 | 3 - | 7 7.2 |
G4 8 | - | 3 1.9 | - | 5 40.6 | - | - | - |
Non N Ir 203 | 375 9.0 p=0.0001 | 418 11.4 p=0.54 | 421 11.2 p=0.018 | 431 11.6 p=0.146 | 434 11.1 p=0.001 | 449 11.1 p=0.001 | 470 12.6 p=0.05 |
Conclusions
This study confirms the feasibility and the safety of ICIs in a large, real-world cohort of patients with NSCLC. The development of irAEs in NSCLC patients treated with immunotherapy may predict better treatment efficacy and overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1509TiP - The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor
Presenter: Laura Mezquita
Session: Poster session 21
1510TiP - Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208)
Presenter: Antonio Vitale
Session: Poster session 21
1515P - Maintenance rucaparib after first-line platinum-based chemotherapy in advanced esophagogastric (OG) adenocarcinoma: Interim results from the PLATFORM trial
Presenter: Anderley Gordon
Session: Poster session 21
1518P - Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study
Presenter: Keun-Wook Lee
Session: Poster session 21
1520P - Perioperative treatment in resectable gastric cancer with spartalizumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): The GASPAR phase II trial
Presenter: Melanie Dos Santos
Session: Poster session 21
1521P - Addition of durvalumab to CROSS in oesophageal adenocarcinoma is feasible and safe
Presenter: Hans Schloesser
Session: Poster session 21